Lipigon Pharmaceuticals AB engages in the development of drugs for diseases caused by disruptions in the body's handling of lipids. It focuses on small molecules, gene therapy, and antisense for patients with lipid disorders and other cardiometabolic risk factors. Lipigon products include P1 lipisense, P3 dyslipidemia and P4 CAP. The company was founded by Stefan Kristoffer Nilsson on April 6, 2010 and is headquartered in Umeå, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company